{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:06:34Z","timestamp":1786115194570,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05730-x","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:45:39Z","timestamp":1785977139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial"],"prefix":"10.1007","author":[{"given":"Shangshang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"6","key":"5730_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.abd.2023.12.004","volume":"99","author":"E Acer","year":"2024","unstructured":"Acer E, Erdo\u011fan HK, A\u011fao\u011flu E, Ba\u015ft\u00fcrk H, Bilgin M, Sara\u00e7o\u011flu ZN (2024) Efficacy and safety of secukinumab in psoriasis: five-year real life experience. An Bras Dermatol 99(6):840\u2013846","journal-title":"An Bras Dermatol"},{"issue":"1","key":"5730_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, Merola JF (2025) Psoriasis. Nat Rev Dis Primers 11(1):45","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"5730_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG (2020) Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 156(6):649\u2013658","journal-title":"JAMA Dermatol"},{"key":"5730_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186455","volume":"14","author":"NC Brembilla","year":"2023","unstructured":"Brembilla NC, Boehncke WH (2023) Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol 14:1186455","journal-title":"Front Immunol"},{"issue":"3","key":"5730_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/bjd\/ljae062","volume":"191","author":"L Cai","year":"2024","unstructured":"Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J (2024) A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 191(3):336\u2013343","journal-title":"Br J Dermatol"},{"key":"5730_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01450-x","author":"L Cai","year":"2025","unstructured":"Cai L, Li C, Li S, Zhang X, Wang G, Yu J, Huang K, Fang H, Ding Y, Wang J, Jiang C, Lu Q, Tao J, Zhang J (2025) Investigation of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis: a multicenter, randomized, double-blind phase II clinical trial. Dermatol Ther (Heidelb). https:\/\/doi.org\/10.1007\/s13555-025-01450-x","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"5730_CR7","volume":"33","author":"\u00d6F Elmas","year":"2020","unstructured":"Elmas \u00d6F, Demirba\u015f A, Kutlu \u00d6, Ba\u011fc\u0131er F, Metin MS, \u00d6zyurt K, Akdeniz N, Atasoy M, T\u00fcrsen \u00dc, Lotti T (2020) Psoriasis and COVID-19: a narrative review with treatment considerations. Dermatol Ther 33(6):e13858","journal-title":"Dermatol Ther"},{"issue":"6","key":"5730_CR8","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jaad.2019.01.039","volume":"80","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Regnier SA, Chirilov A, Hey F, Gilloteau I, Cella D (2019) Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol 80(6):1650\u20131657","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5730_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12325-024-03030-5","volume":"42","author":"X Gao","year":"2025","unstructured":"Gao X, Pan W, Zheng M, Li F, Dong X, Lv D, Guo Z, Li J, Wang X, Geng S (2025) Efficacy and safety analysis in Chinese patients with moderate-to-severe psoriasis from a phase 3 trial: impact of treatment withdrawal and retreatment of ixekizumab. Adv Ther 42(1):334\u2013347","journal-title":"Adv Ther"},{"issue":"3","key":"5730_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/12034754231168851","volume":"27","author":"V Gaudet","year":"2023","unstructured":"Gaudet V, Yap B, Hassan S, Barbeau M (2023) Brodalumab for plaque psoriasis: a Canadian real-world experience at 2-years post-launch. J Cutan Med Surg 27(3):226\u2013235","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"5730_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/bjd\/ljad186","volume":"189","author":"S Gerdes","year":"2023","unstructured":"Gerdes S, Staubach P, Dirschka T, Wetzel D, Weirich O, Niesmann J, da Mota R, Rothhaar A, Ardabili M, Vlasitz G, Feldwisch J, Osterling Koskinen L, Ohlman S, Peloso PM, Brun NC, Frejd FY (2023) Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. Br J Dermatol 189(4):381\u2013391","journal-title":"Br J Dermatol"},{"issue":"4","key":"5730_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL (2016) Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375(4):345\u2013356","journal-title":"N Engl J Med"},{"issue":"10273","key":"5730_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A (2021) Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet (London, England) 397(10273):475\u2013486","journal-title":"Lancet (London, England)"},{"issue":"1","key":"5730_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X (2023) Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther 8(1):437","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"5730_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-024-02110-8","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ (2024) Vunakizumab: first approval. Drugs 84(11):1481\u20131485","journal-title":"Drugs"},{"issue":"3","key":"5730_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40257-025-00928-w","volume":"26","author":"D Kim","year":"2025","unstructured":"Kim D, Yang S, Gill M, Babaei N, Cervantes M, Wu JJ (2025) Next-generation anti-IL-17 agents for psoriatic disease: a pipeline review. Am J Clin Dermatol 26(3):307\u2013320","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"5730_CR17","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/bjd.13691","volume":"172","author":"H Kitchen","year":"2015","unstructured":"Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C (2015) Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol 172(5):1210\u20131221","journal-title":"Br J Dermatol"},{"issue":"4","key":"5730_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C (2014) Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med 371(4):326\u2013338","journal-title":"N Engl J Med"},{"issue":"2","key":"5730_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2023","unstructured":"Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C (2023) Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol 188(2):198\u2013207","journal-title":"Br J Dermatol"},{"issue":"6","key":"5730_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1365-2133.2011.10469.x","volume":"165","author":"MF Otuki","year":"2011","unstructured":"Otuki MF, Reis RC, Cabrini D, Prudente AS, Horinouchi CD, Correr CJ (2011) Patient-reported outcomes in psoriasis research and practice. Br J Dermatol 165(6):1361\u20131362","journal-title":"Br J Dermatol"},{"issue":"2","key":"5730_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Tha\u00e7i D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A (2016) A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 175(2):273\u2013286","journal-title":"Br J Dermatol"},{"issue":"4","key":"5730_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","volume":"11","author":"L Puig","year":"2021","unstructured":"Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, Zolkin NA, Kuryshev IV, Petrov AN, Artemeva AV, Zinkina-Orikhan AV (2021) Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. Dermatol Ther (Heidelb) 11(4):1319\u20131332","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"5730_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76(3):418\u2013431","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5730_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2250918","volume":"20","author":"L Rusi\u00f1ol","year":"2024","unstructured":"Rusi\u00f1ol L, Carmona-Rocha E, Puig L (2024) Durability and long-term outcomes of biologic therapies in psoriasis. Expert Rev Clin Immunol 20(1):71\u201382","journal-title":"Expert Rev Clin Immunol"},{"key":"5730_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2025.01.002","volume":"83","author":"A Saran","year":"2025","unstructured":"Saran A, Nishizaki D, Lippman SM, Kato S, Kurzrock R (2025) Interleukin-17: a pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders. Cytokine Growth Factor Rev 83:35\u201344","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"5730_CR26","first-page":"Cd011535","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L (2023) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane database of systematic reviews 7(7):Cd011535","journal-title":"The Cochrane database of systematic reviews"},{"issue":"2","key":"5730_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","volume":"66","author":"I Sieminska","year":"2024","unstructured":"Sieminska I, Pieniawska M, Grzywa TM (2024) The immunology of psoriasis-current concepts in pathogenesis. Clin Rev Allergy Immunol 66(2):164\u2013191","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"5730_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, Tha\u00e7i D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Gomez NN, Eyerich K (2023) Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol 89(3):486\u2013495","journal-title":"J Am Acad Dermatol"},{"key":"5730_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122991","volume":"355","author":"D Sugumaran","year":"2024","unstructured":"Sugumaran D, Yong ACH, Stanslas J (2024) Advances in psoriasis research: from pathogenesis to therapeutics. Life Sci 355:122991","journal-title":"Life Sci"},{"issue":"10","key":"5730_CR30","first-page":"1063","volume":"20","author":"CY Wang","year":"2021","unstructured":"Wang CY, Foley P, Baker C, Rademaker M (2021) Biological therapy interruption and re-treatment in chronic plaque psoriasis. J Drugs Dermatol 20(10):1063\u20131071","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"5730_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","volume":"92","author":"K Yan","year":"2025","unstructured":"Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J (2025) Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol 92(1):92\u201399","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5730_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","volume":"87","author":"C Zhang","year":"2022","unstructured":"Zhang C, Yan K, Diao Q, Guo Q, Jin H, Yang S, Chen X, Lei T, Wu J, Yu H, Zheng M, Gao X, Sinclair R, Zhu Y, Xu Q, Xu J (2022) A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 87(1):95\u2013102","journal-title":"J Am Acad Dermatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05730-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:45:41Z","timestamp":1785977141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05730-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":32,"alternative-id":["5730"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05730-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of each center approved the phase III trial, with Huashan Hospital, Fudan University serving as the master ethics committee. The ethics approval number for the principal center was 20201231. The study was conducted in accordance with the Declaration of Helsinki (1964) and its later amendments. Informed consent was collected from all participants before enrollment, and participants were informed that no identifiable personal information would be disclosed or recognizable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}